During the past decade, ETG Zamosc conducted 69 clinical trials. In the 10-year time frame, 69 clinical trials started and 25 clinical trials were completed, i.e. on average, 36.2% percent of trials that started reached the finish line to date. In the past 5 years, 47 clinical trials started and 25 clinical trials were completed. i.e. 53.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "ETG Zamosc" #1 sponsor was "Janssen Research & Development, LLC" with 10 trials, followed by "Pfizer" with 8 trials sponsored, "Eli Lilly and Company" with 7 trials sponsored, "Amgen" with 4 trials sponsored and "Galapagos NV" with 4 trials sponsored. Other sponsors include 31 different institutions and companies that sponsored additional 31 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "ETG Zamosc" #1 collaborator was "Parexel" with 2 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "ICON Clinical Research" with 1 trials as a collaborator and "IQVIA Biotech" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "ETG Zamosc" are "Ulcerative Colitis" (10 trials), "Crohn's Disease" (7 trials), "Crohn Disease" (5 trials), "Plaque Psoriasis" (4 trials) and "Psoriasis" (4 trials). Many other conditions were trialed in "ETG Zamosc" in a lesser frequency.

Most popular intervention types in "ETG Zamosc" are "Drug" (64 trials), "Biological" (6 trials), "Other" (4 trials), "Device" (1 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (39 trials), "Guselkumab" (6 trials), "Mirikizumab" (4 trials), "Ustekinumab" (4 trials) and "Guselkumab Dose 1" (3 trials). Other intervention names were less common.

The vast majority of trials in "ETG Zamosc" are 67 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "ETG Zamosc". undefined are not yet recruiting, 16 are recruiting, 15 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 28 completed trials in ETG Zamosc, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in ETG Zamosc, 0 "Phase 1" clinical trials were conducted, 25 "Phase 2" clinical trials and 44 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".